Neurotoxic manifestations of high-dose intrathecal gadolinium administration for CT myelogram

Use of intrathecal gadolinium for contrast-enhanced myelography and cisternography remains off-label and is currently not FDA-approved. We report a 70-year-old male who underwent CT myelogram utilizing off-label high-dose intrathecal gadolinium who developed altered mental status and bilateral heari...

Descripción completa

Detalles Bibliográficos
Autores principales: Malalur, Pannaga, Rajacic, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Complications of Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452073/
https://www.ncbi.nlm.nih.gov/pubmed/32874398
http://dx.doi.org/10.1016/j.radcr.2020.07.084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452073/
https://www.ncbi.nlm.nih.gov/pubmed/32874398
http://dx.doi.org/10.1016/j.radcr.2020.07.084

Ejemplares similares